Drugs / EFGIVANERMIN ALFA
EFGIVANERMIN ALFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02583165 | Nov 2015 → Dec 2018 | cancer | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EFGIVANERMIN ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298030 ↗ |
| Known as | Efgivanermina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298030 ↗ |
| Known as | Efgivanermine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298030 ↗ |
| Known as | MEDI1873 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02583165 ↗ |
| Action | Activate | “MEDI1873 (GITR Agonist)” NCT02583165 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4298030 ↗ |
| Route | Intravenous | “Subjects will receive MEDI1873 by intravenous administration” NCT02583165 ↗ |